Has Matthew Cavey, MD received payments from drug or device companies?

Yes. Drug and device makers reported $22,357 in general payments to Matthew Cavey, MD across 126 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Matthew Cavey, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Matthew Cavey, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Matthew Cavey, MD

Radiation Oncology · Fort Worth, TXNPI 1720031263

Payments from drug & device makers

What this record shows

The money is spread across several categories — other (30.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Bioprotect Medical, Inc. at 38.4% of the total. 2025 is the largest year on record at $9,943, more than ten times the $62 reported in 2019. Among radiation oncology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$22,357in general payments, 2019–2025

Across 126 payments — averaging $177.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Bioprotect Medical, Inc.$9K
Olympus America Inc.$7K
Boston Scientific$1K
Elekta, Inc.$1K
Viewray Technologies Inc$1K
Isoray, Inc$847
plus $2K from 16 others

What the payments were for

Consulting fees$5,00022%
Speaking & faculty fees$1,0004%
Travel & lodging$3,44015%
Food & beverage$6,19328%
Other$6,72330%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Bioprotect Medical, Inc.	19	$8,578
Olympus America Inc.	1	$6,723
Boston Scientific	24	$1,490
Elekta, Inc.	9	$1,388
Viewray Technologies Inc	6	$1,347
Isoray, Inc	16	$847
Accuray Incorporated	14	$705
Palette Life Sciences, Inc.	9	$364
GT Medical Technologies, Inc	2	$172
Theragenics Corporation	2	$167
Blue Earth Diagnostics	6	$139
Myriad Genetic Laboratories, Inc.	2	$70
Progenics Pharmaceuticals, Inc.	3	$63
Novartis	2	$53
Pfizer	2	$44
Civco Medical Instruments	2	$42
Telix Pharmaceuticals	2	$41
Exelixis Inc.	1	$38
Zap Surgical Systems, Inc.	1	$26
Bayer	1	$24
Medtec LLC	1	$21
Novocure Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,357 in reported general payments places this provider in the 90th percentile of 418 radiation oncology providers in Texas.

See all radiation oncology providers in Texas →

Medicare billing

Part B allowed, 2024

$2,213,744

Medicare patients

389

Services billed

8,649

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OrgovyxRelugolix	59	$159,712
Tamsulosin Hcl	834	$18,130
Silodosin	64	$3,362
Tadalafil	56	$2,868
Oxybutynin Chloride ErOxybutynin Chloride	56	$1,265
Ciprofloxacin Hcl	188	$760
Alfuzosin Hcl ErAlfuzosin Hcl	27	$600
Bicalutamide	34	$579
Dutasteride	35	$502
Mometasone Furoate	25	$315
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	19	$80
Terazosin Hcl	12	$59

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Fort Worth

James WelshHouston$421K
Stephen ChunHouston$344K
Jim HsiangCorpus Christi$258K
Chad TangHouston$183K
Phuoc TranHouston$177K
Hak ChoyDallas$119K
Steven LinHouston$105K
Benjamin SchrankHouston$100K
Robert TimmermanDallas$77K
Abhilasha PatelHouston$76K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →